论文部分内容阅读
Although there is now a wide range of in vitro ADME assays and in vivo PK models available to identify and optimize DMPK liabilities in todays drug discovery process, unfavorable PK profile still causes significant attrition of drug candidates for the treatment of certain types of diseases (e.g.anticancer and CNS drugs).